🧬CAR therapies have made it possible to achieve remissions in tumors for which there were previously no treatment options. However, limitations remain, such as toxicities, relapses mediated by antigenic escape, and challenges related to manufacturing, cost, and access.
⚙️To overcome these barriers, we present a modular system that separates a universal signaling module—responsible for activating the therapeutic cells—from one or more interchangeable recognition modules designed to identify tumors, thereby allowing the specificity to be reoriented without having to reengineer the entire cell.
🧩The system allows for the targeted co-assembly of multiple targets onto a single delivery platform, reducing the risk of antigenic escape by enabling the modification of recognition modules when changes occur in tumors. The ability to modulate the presence of complete receptors by discontinuing the infusion of recognition modules will also make it possible to control toxicity and the depletion of therapeutic cells.
🌍The platform is also compatible with universal products, enabling the large-scale production of healthy donor cells with a common signaling module and equipping them with different recognition modules based on each patient’s needs. These universal CARs can be rapidly prepared to target different tumor targets, with the ability to target multiple targets and fine-tune therapeutic activity to enhance the safety, efficacy, and accessibility of these therapies, enabling us to reach all patients in a timely manner.
🔬This innovation, which aims to improve safety (toxicity control), sustained efficacy (by mitigating antigenic escape and “fatigue” of therapeutic cells), and accessibility (standardized manufacturing of the signaling module and rapid “refitting” with recognition modules), is protected by a pending European patent, supplemented by Publications in two types of tumors—multiple myeloma and B-cell neoplasms—confirming the system’s versatility and its potential for patient-specific customization.
🔗 Más información: Instagram
